The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis
NCT06599307
Summary
The goal of this clinical trial is to know if rituximab can improve cognitive and hand functions in secondary progressive multiple sclerosis (SPMS) patients with high disability (EDSS 6.5 or more). The main questions it aims to answer are: Can rituximab improve cognitive and hand functions in SPMS patients? Can rituximab improve the quality of life and the Expanded Disability Status Scale (EDSS) in SPMS patients? Researchers will compare patients who receive rituximab to patient who receive placebo to see the effects of rituximab on cognition, hand functions, quality of life and EDSS. Demographic and clinical data as age, gender, disease duration and EDSS will be obtained from each participant. Participants will perform The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS), The Nine-Hole Peg Test (9-HPT) and The MS-QLQ27 questionnaire at baseline and after one year of receiving either rituximab or placebo.
Eligibility
Inclusion Criteria: 1. Diagnosis of secondary progressive multiple sclerosis by Lorscheider et al's criteria (disability progression by 1 EDSS step in patients with EDSS ≤ 5.5 or 0.5 EDSS step in patients with EDSS ≥ 6 in the absence of a relapse, a minimum EDSS score of 4 and pyramidal functional system (FS) score of 2 and confirmed progression over ≥3 months, including confirmation within the leading FS). 2. Baseline EDSS ≥ 6.5. Exclusion Criteria: 1. Patients received disease modifying therapy for SPMS other than rituximab. 2. Clinical relapse in the last 3 months before recruitment. 3. Patients with documented hypersensitivity or contraindication to rituximab. 4. Patients with concomitant neurologic conditions that may affect cognitive or hand functions.
Conditions2
Interventions1
Related trials
- A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL — InnoCare Pharma Inc.
- A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma — University of Birmingham
- A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors — LaNova Medicines Limited
- A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors — BeOne Medicines
- A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) — Dizal (Jiangsu) Pharmaceutical Co., Ltd.
- A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma — Guangzhou Lupeng Pharmaceutical Company LTD.
- A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma — Second Affiliated Hospital, School of Medicine, Zhejiang University
- A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma — Ruijin Hospital
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06599307